Sam Ghoubrial
Internal Medicine · Wadsworth, OHNPI 1003892217
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $764 and has fallen 80.5% since, to $149 in 2023.
Across 104 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$336
- Lilly USA, LLC$118
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
- Otsuka America Pharmaceutical, Inc.$85
- Novo Nordisk$83
- Biohaven Pharmaceutical Holding Company Ltd.$77
- plus $792 from 25 others
What the payments were for
- Food & beverage$1,582100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $336 |
| Lilly USA, LLC | 8 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Novo Nordisk | 6 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $77 |
| Supernus Pharmaceuticals, Inc. | 5 | $75 |
| Avanir Pharmaceuticals, Inc. | 4 | $65 |
| AstraZeneca | 4 | $54 |
| Pfizer | 4 | $52 |
| Astellas Pharma US Inc | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Boehringer Ingelheim | 3 | $41 |
| Kyowa Kirin, Inc. | 3 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Novartis | 2 | $31 |
| GSK | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $28 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Inogen, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Bayer | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| UCB, Inc. | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$1,582 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Chloride | 32 | $554 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $330 |
| Rosuvastatin Calcium | 15 | $312 |
| Atorvastatin Calcium | 16 | $212 |
| Allopurinol | 11 | $137 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Wadsworth
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
- Vincent MartinCincinnati$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.